Anacaulase topical Pregnancy and Breastfeeding Warnings
Brand names: NexoBrid
Anacaulase topical Pregnancy Warnings
The manufacturer makes no recommendation regarding use during pregnancy.
US FDA pregnancy category: Not Assigned
No data available on the use of this drug in pregnant women to inform a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
No significant adverse effect was reported in preclinical studies; however, severe maternal toxicities were observed, and the tolerable maternal exposure level was much lower compared to the maximum human exposure. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Anacaulase topical Breastfeeding Warnings
The manufacturer makes no recommendation regarding use during lactation.
Excreted into human milk: Data not available
Excreted into animal milk: Data not available
Comments:
-The effects in the nursing infant or on milk production are unknown.
-The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for this drug and any potential adverse effects on the breastfed infant from this drug or from the underlying maternal condition.
See also
References for pregnancy information
- (2022) "Product Information. Nexobrid (anacaulase topical)." Vericel Corporation
References for breastfeeding information
- (2022) "Product Information. Nexobrid (anacaulase topical)." Vericel Corporation
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
